The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Serum mass spectrometry analysis in primary ovarian cancer (OC) treated with surgery and adjuvant chemotherapy (CT).
Heinrich Roder
Employment or Leadership Position - Biodesix (I); Biodesix
Stock Ownership - Biodesix (I); Biodesix
Sabine Kasimir-Bauer
No relevant relationships to disclose
Rainer Kimmig
No relevant relationships to disclose
Pauline Wimberger
No relevant relationships to disclose
Robert Zeillinger
No relevant relationships to disclose
Dan Cacsire Castillo-Tong
No relevant relationships to disclose
Jalid Sehouli
No relevant relationships to disclose
Ignace Vergote
No relevant relationships to disclose
Sven Mahner
No relevant relationships to disclose
Joanna Roder
Employment or Leadership Position - Biodesix (I); Biodesix
Stock Ownership - Biodesix (I); Biodesix
Julia Grigorieva
Employment or Leadership Position - Biodesix (I); Biodesix
Stock Ownership - Biodesix (I); Biodesix
Krista Meyer
Employment or Leadership Position - Biodesix
Bahriye Aktas
No relevant relationships to disclose